丰明乾博士　教授　博士生导师
教育经历
1993.9-1997.7 西北农林科技大学农学系作物遗传育种农学学士学位
1997.9-2000.7 西北农林科技大学生命科学技术学院生物化学与分子生物学理学硕士学位
2005.9-2008.7 南京大学生命科学院生物学理学博士学位
科研与学术工作经历
2000.7-2005.9 华中农业大学生命科学技术学院讲师
2008.10-2015.11 美国NIH，博士后，助理研究员（Research Fellow）
2011.12-现在华中农业大学生命科学技术学院教授
研究方向
抗体工程，肿瘤免疫学，病毒免疫学
代表性研究成果
论文
1. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015, 6:6536
2. Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Nat Sci Acad USA. 2013, 110:E1083-91.
3.　Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014, 588:377-82.
4. Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60:576-87
5. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, and Ho M. A human single-domain antibody elicits potent anti-tumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther, 2013, 12: 416-26.
6. 　Feng M., Kim H., Phung Y., and Ho M. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer, 2011, 128: 2246-2247.
7. 　Feng M., Zhang J., Anver M, Hassan R., and Ho M. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer, 2011, 2: 123-131.
8. 　Ho M., Feng M., Fisher R.J., Rader C., and Pastan I. A novel high affinity human monoclonal antibody to mesothelin. Int J Cancer., 2011, 128: 2020-2030.
9. Xiang X, Feng M,Felder M, Connor JP, Man YG, Patankar MS, and Ho M. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer, 2011, 2:280-91.
10. Xiang X., Phung Y.,Feng M., Nagashima K., Zhang J., Broaddus V.C., Hassan R., FitzGerald D., and Ho M. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. Plos one, 2011, 6: e14640.
11. Yu L., Feng M., Kim H., Phung Y., Kleiner D.E., Gores G..J., Qian M., Wang X.W., and Ho M. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer,2010, 1:141-149.
授权专利
1. Human monoclonal antibodies specific for glypican-3 and use thereof. PCT application no. PCT/US2012/034186; International filling date 19/Apr/2012. Inventors: Ho M,Feng M, Gao W, Kim H, and Dimiter D.
2. Mesothelin antibodies and methods for eliciting potent antitumor activity. U.S. PCT/US2013/059883. Inventors: Ho M, Pastan I, Dimitrov DS, Tang Z, Feng M, and Gao W
主讲课程
免疫学
研究生招生专业
生物化学与分子生物学
联系方式
实验室电话：
电子邮箱：fengmingqian@mail.hzau.edu.cn
办公地点：第一综合楼A519
实验室介绍及网址：